Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML. - sprookjes - yvandenbroek - TriplyDB

Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.

Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.

http://www.wikidata.org/entity/Q37061964

about

Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning Sociodemographic disparities in chemotherapy and hematopoietic cell transplantation utilization among adult acute lymphoblastic and acute myeloid leukemia patients Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome.Automated detection of residual cells after sex-mismatched stem-cell transplantation - evidence for presence of disease-marker negative residual cells.Safety of conditioning agents for allogeneic haematopoietic transplantation.Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).Neurological complications of transplantation: part I: hematopoietic cell transplantation.Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT.A modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia receiving allogeneic stem cell transplants.Validation of the European Group for Blood and Marrow Transplantation (EBMT) risk score in patients receiving allogeneic hematopoietic stem cell transplantation at a single center in Japan.

P2860

Q33770125-BB44C72E-839A-4238-A504-FF91309271B8 Q34975409-D392F9D4-A900-45CA-8CB5-46D476107A62 Q36337955-4A061933-B6E5-4DA4-8843-860637783AA8 Q36579060-6FBF18F0-F142-40ED-84BA-0F76C23F6B8F Q36579081-422E28B7-635F-42C3-B5AC-5623DD927346 Q37227738-5DE54AF4-6A5D-4C00-B8CD-076E9A15E89B Q37510948-7A319689-7425-464A-B061-A482700D7523 Q37739860-21C8F8D2-4242-48BF-8ABD-26658B18BDA5 Q38029953-6DD9C9C4-FEE3-4CDD-8F54-5AA03C31DA34 Q38132157-8390AC85-D0C1-49A7-8B1F-7C9FB00A4A8D Q44919804-C2B3D214-488E-4BE2-9741-CFCA0C47A3D8 Q52898922-C9877658-BC5B-4D19-A793-C7AD36132DF6 Q53061253-5376740C-0E44-4C1A-B297-58248808B6AB

P2860

Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.

http://www.wikidata.org/entity/Q37061964

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 January 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.

@en

Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.

@nl

type

label

Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.

@en

Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.

@nl

prefLabel

Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.

@en

Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.

@nl

P1433

Q37061964-2E32DDF4-BCEB-4FC1-8DF4-7609ED119637

P1476

Q37061964-3C53EB9B-ABC6-46B5-9DB6-1863A5F9A5BD

P2093

Q37061964-78A96F5A-1F8F-4DA3-AEE8-ECC0D9D407CE

P2860

Q37061964-03BB7A88-2AA8-428B-877D-0ED270B76A23

Q37061964-08F7A757-7A32-408B-A3CE-1751D7059579

Q37061964-0A460A60-A4FA-4F63-B1E4-844E12D4010D

Q37061964-0C1273F4-FF33-4B5F-B5F5-0EAEA7051E95

Q37061964-10855936-41B8-460D-B1AC-5B59FB719480

Q37061964-11DBA45F-11EB-4DE1-9DD3-ABF254030173

Q37061964-15E37889-00A0-4B6F-ADA0-983D77DBE02B

Q37061964-18714DF7-7B92-477A-9E12-7B4D5BA59E6B

Q37061964-1AB37750-FE9F-4CFC-ACF7-2B8312B15921

Q37061964-1C01A07A-29F5-4920-BD77-FB2E5956F7ED

P2888

Q37061964-96B55862-5F7C-4789-A2F6-CFB2D251D2C0

P304

Q37061964-EEF8BC5C-CC38-490B-8430-F8BA17C6B9BD

P31

Q37061964-5F126BC7-7455-4E41-98C7-B328D0BBF2A3

P356

Q37061964-6FEB605C-41D1-4D50-99A3-7AA9B3C615F5

P407

Q37061964-C3A0E3E6-B0AE-48B2-809F-039C5243121B

P433

Q37061964-0BD017EB-6FE2-427D-B51D-342165D9D15D

P478

Q37061964-9772698A-A909-4272-853C-B9D968FD4543

P577

Q37061964-124A42CF-E316-479D-B2D9-AD465B5537DE

P5875

Q37061964-D682C23F-0255-42EA-9E60-CA59938DAE49

P6179

Q37061964-35AC759B-3D02-47E4-84C0-5529FE2F5C5E

P698

Q37061964-85123D5C-7AE5-4CF8-9118-47144BC22569

P356

P1433

Bone Marrow Transplantation

P1476

Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.

@en

P2093

C F Craddock

http://www.w3.org/2001/XMLSchema#string

P2860

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Preferential induction of apoptosis for primary human leukemic stem cells.

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial.

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches.

Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.

P2888

P304

415-423

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BMT.1705975

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5641441

http://www.w3.org/2001/XMLSchema#string

P6179

1040868100

http://www.w3.org/2001/XMLSchema#string

P698

18209726

http://www.w3.org/2001/XMLSchema#string